Investor Presentaiton

For personal use only Near-term growth opportunities Expansion into new geographic markets • • Launch Illuccix with distribution partner (in progress) NOBLE Registry expansion 1. National Evidence-based Healthcare Collaborating Agency. Health Technology Assessment. Telix Pharmaceuticals Limited (ASX: TLX) • DuChemBic partnership NECA HTA1 completed Illuccix kit sales have commenced, pursuing reimbursement under local regulatory exemption • China Grand Pharma partnership NMPA consultations have commenced (Mainland China) Regulatory filings for Illuccix Q1 2022 (Taiwan, Hong Kong) • • Largest Asia Pacific market opportunity Key bridging clinical trials have been successfully completed (TLX591-CDx & TLX250-CDx) 529 52 TELIX PHARMACEUTICALS

View entire presentation